Alzheimer disease: progress or profit? (original) (raw)

Nature Medicine volume 12, pages 780–784 (2006)Cite this article

Alzheimer disease is the most common cause of dementia. According to the World Health Organization, an estimated 37 million people worldwide currently have dementia; Alzheimer disease affects about 18 million of them1.

Increasing age is the greatest risk factor for Alzheimer disease. Its prevalence approximately doubles every five years after the age of 60—one in 10 individuals over 65 years and nearly half of those over 85 are affected by the disease. So, although the incidence rate of Alzheimer disease is not thought to be changing, Alzheimer disease poses one of the greatest threats to the future of healthcare systems, owing to the anticipated demographic shift to an aging population—the number of people worldwide above the age of 60 years is expected to double over the next 25 years.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Subscribe to this journal

Receive 12 print issues and online access

$209.00 per year

only $17.42 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

References

  1. Vas, C.J. et al. Alzheimer's Disease: The Brain Killer World Health Organization. (2001).
  2. Herbert, L.E., Beckett, L.A., Scherr, P.A. & Evans, D.A. Alzheimer. Dis. Assoc. Disord. 15, 169–173 (2001).
    Article Google Scholar
  3. Alzheimer's Disease International. Factsheet 3: The prevalence of dementia. http://www.alz.co.uk/adi/pdf/3preval.pdf (1999).
  4. National Institute on Aging, National Institutes of Health. 2001–2002 Alzheimer's Disease Progress Report. National Institutes of Health publication number 03-5333, p. 2 (July 2003).
  5. Alzheimer's Disease Research, Prevention and Care Act of 2003, 108th Congress, 1st Session S.566 in the Senate of the United States (2003).
  6. Lewin Group. Saving Lives, Saving Money: Dividends for Americans Investing in Alzheimer Research. (Washington, DC, 2004).
  7. Hodes, Nat. Med. 770–773 (2006).
  8. Gearing, M. et al. Neurology 45, 461–466 (1995).
    Article CAS Google Scholar
  9. Lanctot, K.L. et al. CMAJ 169, 557–564 (2003).
    PubMed PubMed Central Google Scholar
  10. Farlow, M.R. Int. J. Clin. Pract. Suppl. 127, 37–44 (2002).
    CAS Google Scholar
  11. Alzheimer's Association Fact Sheet: FDA-approved cholinesterase inhibitors. http://www.alz.org/Resources/FactSheets/FS_Cholinesteraseinhibtors.pdf (2005).
  12. Tabet, N., Birks, J. & Grimley Evans, J. Cochrane Database Syst. Rev. 4, CD002854 (2000).
    Google Scholar
  13. Miller, E.R. et al. Ann. Intern. Med. 142, 37–46 (2005).
    Article CAS Google Scholar
  14. Tariot, P.N. & Federoff, H.J. Alzheimer Dis. Assoc. Disord. 17 Suppl 4, S105–S113 (2003).
    Article CAS Google Scholar
  15. Birks, J. Cochrane Database Syst. Rev. 1, CD005593 (2006).
    Google Scholar
  16. Schechter, L.E. et al. J. Pharmacol. Exp. Ther. 314, 1274–1289 (2005).
    Article CAS Google Scholar
  17. Nicoll, J.A. et al. Nat. Med. 9, 389–390 (2003).
    Article Google Scholar

Download references

Author information

Authors and Affiliations

  1. Wood Mackenzie, London, EC2N 1HN, UK
    Claire Mount & Christian Downton

Authors

  1. Claire Mount
    You can also search for this author inPubMed Google Scholar
  2. Christian Downton
    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence toClaire Mount.

Rights and permissions

About this article

Cite this article

Mount, C., Downton, C. Alzheimer disease: progress or profit?.Nat Med 12, 780–784 (2006). https://doi.org/10.1038/nm0706-780

Download citation

This article is cited by